Nurse Practitioner in Fords, NJ Accepting Medicare
5 Nurse Practitioner nurses found. Showing 1 - 5
 Stephanie Szylar, APN Nurse Practitioner - Gerontology Medicare: Accepting Medicare Assignments Practice Location: 63 Remmey St, Fords, NJ 08863 Phone: 732-221-7530 |
Selasi Darlene Akator, MSN,APRN,FNP-C Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 21 Thompson Ave, Fords, NJ 08863 Phone: 201-341-1711 |
Natasha Aferibea Osei, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2 William St, Fords, NJ 08863 Phone: 646-200-1262 |
Priscilla Ramos, Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 91 Mary Ave, Fords, NJ 08863 Phone: 732-585-7211 |
Ann Marie Linden, APN Nurse Practitioner - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 259 New Brunswick Ave Ste 202, Fords, NJ 08863 Phone: 732-293-9883 |
News Archive
UArizona researcher aims to deliver statins effectively into the brain of stroke patients
Every year in the United States, about 800,000 people experience a stroke. Many are left with neurological complications such as paralysis on one side of the body, speech and language problems, vision issues, behavioral changes, and memory loss.
Kraft Asia Pacific has missed a golden opportunity to show leadership in the battle against childhood obesity
Australian Medical Association President, Dr Bill Glasson, said today that Kraft Asia Pacific has missed a golden opportunity to show leadership in the battle against the epidemic of childhood obesity by not following its US counterpart and modifying advertising of its products to children under the age of 12.
Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
New FDA-approved method for detecting diabetic neuropathy
Details of a new method to detect diabetic neuropathy in patients in less than five minutes using their sweat glands was presented today at the American Association of Clinical Endocrinologists 22nd Annual Scientific and Clinical Congress in Phoenix, Arizona by Aaron I. Vinik, M.D., Ph.D., F.C.P., M.A.C.P., F.A.C.E., Professor of Medicine and Director of Research and the Neuroendocrine Unit at Eastern Virginia Medical School.
› Verified 7 days ago